IASLC World Conference on Lung Cancer 2020

At the IASLC WCLC 2020 virtual meeting, Boehringer Ingelheim presented the latest updates on the afatinib* clinical trials program in advanced non-small cell lung cancer (NSCLC).


Please see below for more information and a downloadable version of the publication.


Virtual exhibit


Click here to view our latest virtual exhibit.


Thursday 28 January – Sunday 31 January, 2021
Virtual format

Browse through the publications below to learn more about our latest clinical trials with afatinib.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Thursday 28 January – Sunday 31 January, 2021
START: Real-world study on sequential therapy with first-line afatinib in Chinese patients with EGFRm+ advanced NSCLC
Author(s): Zhou et al.
Tumor Type(s): non-small cell lung cancer (NSCLC)
Abstract Number: #625
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.


*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.


© 2021 Boehringer Ingelheim International GmbH. All rights reserved.


Page last updated: January 2021